Neuphoria Therapeutics Inc’s filing revealed that its 10% Owner Lynx1 Capital Management LP acquired Company’s shares for reported $3.28 million on Oct 21 ’25. In the deal valued at $5.14 per share,639,110 shares were bought. As a result of this transaction, Lynx1 Capital Management LP now holds 875,328 shares worth roughly $4.28 million.
H.C. Wainwright upgraded its Neuphoria Therapeutics Inc [NEUP] rating to a Buy from a a Neutral in a research note published recently. A number of analysts have revised their coverage, including Maxim Group’s analysts, who remained covering the stock and in late September has reiterated a ‘”a Buy”‘ rating for it. H.C. Wainwright began covering NEUP with “Buy” recommendation on January 10, 2022. Evercore ISI started covering the stock on January 10, 2022. It rated NEUP as “an Outperform”.
Price Performance Review of NEUP
On Tuesday, Neuphoria Therapeutics Inc [NASDAQ:NEUP] saw its stock fall -0.20% to $4.89. Over the last five days, the stock has gained 15.88%. Neuphoria Therapeutics Inc shares have risen nearly 7.24% since the year began. Nevertheless, the stocks have risen 42.57% over the past one year. While a 52-week high of $21.40 was reached on 10/07/25, a 52-week low of $2.77 was recorded on 01/02/25.
Levels Of Support And Resistance For NEUP Stock
The 24-hour chart illustrates a support level at 4.73, which if violated will result in even more drops to 4.58. On the upside, there is a resistance level at 5.11. A further resistance level may holdings at 5.34.
How much short interest is there in Neuphoria Therapeutics Inc?
A steep rise in short interest was recorded in Neuphoria Therapeutics Inc stocks on 2025-10-31, growing by 0.28 million shares to a total of 0.3 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-30 was 25130.0 shares. There was a rise of 91.74%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on January 10, 2022 when Cantor Fitzgerald began covering the stock and recommended ‘”an Overweight”‘ rating along with a $52 price target.
